Cargando…

Survivin 2α: a novel Survivin splice variant expressed in human malignancies

BACKGROUND: Survivin and its alternative splice forms are involved in critical cellular processes, including cell division and programmed cell death. Survivin is expressed in the majority of human cancers, but minimally in differentiated normal tissues. Expression levels correlate with tumor aggress...

Descripción completa

Detalles Bibliográficos
Autores principales: Caldas, Hugo, Honsey, Laura E, Altura, Rachel A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC554981/
https://www.ncbi.nlm.nih.gov/pubmed/15743529
http://dx.doi.org/10.1186/1476-4598-4-11
_version_ 1782122525834084352
author Caldas, Hugo
Honsey, Laura E
Altura, Rachel A
author_facet Caldas, Hugo
Honsey, Laura E
Altura, Rachel A
author_sort Caldas, Hugo
collection PubMed
description BACKGROUND: Survivin and its alternative splice forms are involved in critical cellular processes, including cell division and programmed cell death. Survivin is expressed in the majority of human cancers, but minimally in differentiated normal tissues. Expression levels correlate with tumor aggressiveness and resistance to therapy. RESULTS: In the present study, we identify and characterize a novel survivin isoform that we designate survivin 2α. Structurally, the transcript consists of 2 exons: exon 1 and exon 2, as well as a 3' 197 bp region of intron 2. Acquisition of a new in-frame stop codon within intron 2 results in an open reading frame of 225 nucleotides, predicting a truncated 74 amino acid protein. Survivin 2α is expressed at high levels in several malignant cell lines and primary tumors. Functional assays show that survivin 2α attenuates the anti-apoptotic activity of survivin. Subcellular localization and immunoprecipitation of survivin 2α suggests a physical interaction with survivin. CONCLUSION: We characterized a novel survivin splice variant that we designated survivin 2α. We hypothesize that survivin 2α can alter the anti-apoptotic functions of survivin in malignant cells. Thus survivin 2α may be useful as a therapeutic tool in sensitizing chemoresistant tumor cells to chemotherapy.
format Text
id pubmed-554981
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5549812005-03-20 Survivin 2α: a novel Survivin splice variant expressed in human malignancies Caldas, Hugo Honsey, Laura E Altura, Rachel A Mol Cancer Research BACKGROUND: Survivin and its alternative splice forms are involved in critical cellular processes, including cell division and programmed cell death. Survivin is expressed in the majority of human cancers, but minimally in differentiated normal tissues. Expression levels correlate with tumor aggressiveness and resistance to therapy. RESULTS: In the present study, we identify and characterize a novel survivin isoform that we designate survivin 2α. Structurally, the transcript consists of 2 exons: exon 1 and exon 2, as well as a 3' 197 bp region of intron 2. Acquisition of a new in-frame stop codon within intron 2 results in an open reading frame of 225 nucleotides, predicting a truncated 74 amino acid protein. Survivin 2α is expressed at high levels in several malignant cell lines and primary tumors. Functional assays show that survivin 2α attenuates the anti-apoptotic activity of survivin. Subcellular localization and immunoprecipitation of survivin 2α suggests a physical interaction with survivin. CONCLUSION: We characterized a novel survivin splice variant that we designated survivin 2α. We hypothesize that survivin 2α can alter the anti-apoptotic functions of survivin in malignant cells. Thus survivin 2α may be useful as a therapeutic tool in sensitizing chemoresistant tumor cells to chemotherapy. BioMed Central 2005-03-02 /pmc/articles/PMC554981/ /pubmed/15743529 http://dx.doi.org/10.1186/1476-4598-4-11 Text en Copyright © 2005 Caldas et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Caldas, Hugo
Honsey, Laura E
Altura, Rachel A
Survivin 2α: a novel Survivin splice variant expressed in human malignancies
title Survivin 2α: a novel Survivin splice variant expressed in human malignancies
title_full Survivin 2α: a novel Survivin splice variant expressed in human malignancies
title_fullStr Survivin 2α: a novel Survivin splice variant expressed in human malignancies
title_full_unstemmed Survivin 2α: a novel Survivin splice variant expressed in human malignancies
title_short Survivin 2α: a novel Survivin splice variant expressed in human malignancies
title_sort survivin 2α: a novel survivin splice variant expressed in human malignancies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC554981/
https://www.ncbi.nlm.nih.gov/pubmed/15743529
http://dx.doi.org/10.1186/1476-4598-4-11
work_keys_str_mv AT caldashugo survivin2aanovelsurvivinsplicevariantexpressedinhumanmalignancies
AT honseylaurae survivin2aanovelsurvivinsplicevariantexpressedinhumanmalignancies
AT alturarachela survivin2aanovelsurvivinsplicevariantexpressedinhumanmalignancies